nivolumab, ipilimumab and panitumumab in mcrc
Published 4 years ago • 206 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
5:19
i-o therapy in mcrc: ipilimumab nivolumab
-
1:05
nivolumab and ipilimumab combination in frontline mcrc
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
2:43
paradigm: panitumumab plus mfolfox6 in ras wt mcrc
-
2:42
paradigm: panitumumab versus bevacizumab in ras-wt mcrc
-
1:00
prime-hcc: ipilimumab and nivolumab in liver cancer
-
1:04
nci9673: nivolumab with or without ipilimumab in anal cancer
-
2:35
panama: addition of maintenance panitumumab does not affect qol in mcrc
-
1:37
panitumumab data presented at esmo 2016: depth of response and selecting the right patients
-
0:33
panitumumab mfolofox6 as the new standard of care for ras wt metastatic colorectal cancer
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
1:55
neoadjuvant ipilimumab plus nivolumab in stage iii melanoma
-
2:09
checkmate 032: nivolumab/ipilimumab for urothelial carcinoma
-
3:01
deeper: m-folfoxiri and cetuximab versus bevacizumab in mcrc
-
0:53
philip philip, md on the importance of ipilimumab prior to nivolumab in mcrc patients
-
2:43
current trials in colorectal cancer investigating panitumumab
-
2:00
dr. overman on nivolumab and ipilimumab in patients with msi-h crc
-
1:04
exploring regorafenib and nivolumab as treatment for colorectal cancer
-
2:01
nivolumab, ipilimumab in metastatic colorectal cancer